{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-004172","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.558130+00:00","generated_at":"2026-06-06T22:27:26.104181+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ABVC BioPharma enters $1M convertible note financing with Lind Global Fund II","bullets":["Issued $1,000,000 secured convertible note to Lind Global Fund II at $833,333 purchase price (16.7% OID).","Conversion price: lesser of $3.50 fixed or 90% of avg three lowest VWAPs over 20 days; fixed for first 180 days.","Warrant for 1,000,000 shares at $2.00/share exercises cashless under certain conditions; 5-year term.","Company grants Lind 18-month right of first refusal for up to 10% of any subsequent equity financing.","Allele Capital Partners and Wilmington Capital Securities acted as placement agents; received 25,000-share warrant."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-004172","json":"https://secwatch.observer/filing/0001213900-24-004172.json","markdown":"https://secwatch.observer/filing/0001213900-24-004172.md","text":"https://secwatch.observer/filing/0001213900-24-004172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/0001213900-24-004172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:27:26.104181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"321b69da1404faf7b7399ec3e92ac1d52771d744","claim":"ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with Lind Global Fund II, LP valued at $1,000,000 (effective 2024-01-17).","evidence_excerpt":"On January 17, 2024, ABVC BioPharma, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Lind Global Fund II, LP (“ Lind ”), pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,000,000 (the “ Offering ”), for a purchase price of $833,333","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/0001213900-24-004172-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lind Global Fund II, LP"},{"label":"Value","value":"$1,000,000"},{"label":"Effective","value":"2024-01-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}